
Pharmaceutical Executive Daily: FDA Approves Three New Therapies
FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, FDA approves three new therapies — Genentech’s Gazyva for kidney disease, Alexion’s Klygefa for myasthenia gravis, and Teva’s Igalmi for psychiatric agitation — a dealmaking roundup covers Johnson & Johnson’s $2.2 billion acquisition of Ollin Biosciences, Eli Lilly’s up to $1.5 billion deal for Calytrix Bio, AmyriAD Therapeutics’ acquisition of the AD04 Alzheimer’s program, and Sanofi’s collaboration with Seawolf Therapeutics, and Ron Lanton speaks with Kevin Caldwell of Ossium Health on rebuilding bone marrow transplants around deceased-donor marrow.
FDA has
A wave of dealmaking
Finally, Ron Lanton
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
Related to this article







